NKTX
Nkarta Inc
Halal Rating :
Last Price
$2.46
Last updated:
Market Cap
-
7D Change
6.49%
1 Year Change
-68.78%
Company Overview
Industries
Exchange
Next Earnings Date
Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. The company's primary focus is on developing allogeneic, off-the-shelf NK cell therapy candidates for the treatment of various types of blood cancers and solid tumors. The company utilizes its proprietary platform technology to engineer and enhance the cancer-fighting properties of NK cells.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Nkarta Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.